Learning Objectives of this webinar:
- Understand the key challenges when it comes to scaling up cell manufacturing
- Learn about innovative systems and technologies implemented by industry leaders like ImmuneBridge and National Resilience to enhance scalability and efficiency in cell manufacturing
- Gain insights into how advancements in automation and platform development are shaping the next generation of safer and more effective cell therapies.
- Gather insights in cell therapy characterisation and quality control when scaling up manufacturing.
Cell manufacturing faces challenges such as maintaining consistency, scalability, and cost-effectiveness. Variability in cell behaviour, strict quality control requirements, and complex regulatory approvals make large-scale production difficult. Additionally, ensuring sterility, optimizing automation, and managing high production costs remain key obstacles in advancing efficient and reliable cell manufacturing processes.
We’ve invited speakers from both ImmuneBridge and National Resilience to discuss about the systems they have in place to develop and characterize scalable cell therapies. Herein, our audience will learn about the various considerations when it comes to developing a scalable cell manufacturing platforms, qualifying them, and how it can help advanced scalable cell therapy solutions.
Register now to discover how cell therapy manufacturing has advanced to be prepared to deliver the next generation of safer and more effective cell therapies.